We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Optimization of IV Ketamine for Treatment Resistant Depression

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00768430
First Posted: October 8, 2008
Last Update Posted: January 31, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Icahn School of Medicine at Mount Sinai
Information provided by (Responsible Party):
Sanjay Johan Mathew, Baylor College of Medicine
Results First Submitted: September 5, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Major Depressive Disorder (MDD)
Treatment Resistant Depression (TRD)
Interventions: Drug: Ketamine
Drug: Midazolam

  Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Ketamine Ketamine
Midazolam Midazolam
Total Total of all reporting groups

Baseline Measures
   Ketamine   Midazolam   Total 
Overall Participants Analyzed 
[Units: Participants]
 48   25   73 
Age 
[Units: Years]
Mean (Standard Deviation)
 46.9  (12.8)   42.7  (11.6)   44.8  (12.2) 
Gender 
[Units: Participants]
     
Female   27   11   38 
Male   21   14   35 
Region of Enrollment 
[Units: Participants]
     
United States   48   25   73 


  Outcome Measures

1.  Primary:   MADRS   [ Time Frame: 24 hours post-infusion ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Limitations of our trial include stringent enrollment criteria due to concerns about ketamine’s psychoactive effects and abuse liability. A proportion of screened patients (17.2%) refused or were unable to tolerate psychotropic washout.


  More Information